218 related articles for article (PubMed ID: 24126537)
41. Are cognitive changes progressive in prediagnostic HD?
Stout JC; Weaver M; Solomon AC; Queller S; Hui S; Johnson SA; Gray J; Beristain X; Wojcieszek J; Foroud T
Cogn Behav Neurol; 2007 Dec; 20(4):212-8. PubMed ID: 18091069
[TBL] [Abstract][Full Text] [Related]
42. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
43. The potential of composite cognitive scores for tracking progression in Huntington's disease.
Jones R; Stout JC; Labuschagne I; Say M; Justo D; Coleman A; Dumas EM; Hart E; Owen G; Durr A; Leavitt BR; Roos R; O'Regan A; Langbehn D; Tabrizi SJ; Frost C
J Huntingtons Dis; 2014; 3(2):197-207. PubMed ID: 25062862
[TBL] [Abstract][Full Text] [Related]
44. Factors contributing to institutionalization in patients with Huntington's disease.
Rosenblatt A; Kumar BV; Margolis RL; Welsh CS; Ross CA
Mov Disord; 2011 Aug; 26(9):1711-6. PubMed ID: 21538527
[TBL] [Abstract][Full Text] [Related]
45. What is the impact of education on Huntington's disease?
López-Sendón JL; Royuela A; Trigo P; Orth M; Lange H; Reilmann R; Keylock J; Rickards H; Piacentini S; Squitieri F; Landwehrmeyer B; Witjes-Ane MN; Jurgens CK; Roos RA; Abraira V; de Yébenes JG;
Mov Disord; 2011 Jul; 26(8):1489-95. PubMed ID: 21432905
[TBL] [Abstract][Full Text] [Related]
46. The current clinical management of Huntington's disease.
Phillips W; Shannon KM; Barker RA
Mov Disord; 2008 Aug; 23(11):1491-504. PubMed ID: 18581443
[TBL] [Abstract][Full Text] [Related]
47. [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features].
Bantubungi K; Blum D
Rev Med Brux; 2007; 28(5):413-21. PubMed ID: 18069515
[TBL] [Abstract][Full Text] [Related]
48. [Huntington chorea: clniical and molecular analysis in Asturian patients].
Hernando I; Alvarez V; García Martínez A; Salas Puig J; Fernández Uría D; Martínez C; Vidal Sánchez JA; Lahoz C; Coto E
Neurologia; 1999 Jan; 14(1):11-5. PubMed ID: 10079686
[TBL] [Abstract][Full Text] [Related]
49. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
50. A double blind evaluation of cognitive decline in a Norwegian cohort of asymptomatic carriers of Huntington's disease.
van Walsem MR; Sundet K; Retterstøl L; Sundseth Ø
J Clin Exp Neuropsychol; 2010 Jul; 32(6):590-8. PubMed ID: 19916101
[TBL] [Abstract][Full Text] [Related]
51. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease.
Rao AK; Muratori L; Louis ED; Moskowitz CB; Marder KS
Mov Disord; 2008 Jun; 23(8):1100-7. PubMed ID: 18412252
[TBL] [Abstract][Full Text] [Related]
52. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning.
Reedeker N; Van Der Mast RC; Giltay EJ; Van Duijn E; Roos RA
Mov Disord; 2010 Aug; 25(11):1612-8. PubMed ID: 20629165
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic criteria for Huntington's disease based on natural history.
Reilmann R; Leavitt BR; Ross CA
Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
[TBL] [Abstract][Full Text] [Related]
54. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
Curtis A; Mitchell I; Patel S; Ives N; Rickards H
Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
[TBL] [Abstract][Full Text] [Related]
55. Genetic features of Huntington disease in Cuban population: implications for phenotype, epidemiology and predictive testing.
Vázquez-Mojena Y; Laguna-Salvia L; Laffita-Mesa JM; González-Zaldívar Y; Almaguer-Mederos LE; Rodríguez-Labrada R; Almaguer-Gotay D; Zayas-Feria P; Velázquez-Pérez L
J Neurol Sci; 2013 Dec; 335(1-2):101-4. PubMed ID: 24054538
[TBL] [Abstract][Full Text] [Related]
56. Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis.
Shannon KM
Handb Clin Neurol; 2011; 100():3-13. PubMed ID: 21496568
[TBL] [Abstract][Full Text] [Related]
57. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.
Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC
Mov Disord; 2013 Dec; 28(14):1995-2001. PubMed ID: 24123464
[TBL] [Abstract][Full Text] [Related]
58. Unified Huntington's disease rating scale: clinical practice and a critical approach.
Klempír J; Klempírova O; Spacková N; Zidovská J; Roth J
Funct Neurol; 2006; 21(4):217-21. PubMed ID: 17367582
[TBL] [Abstract][Full Text] [Related]
59. Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease.
Witjes-Ané MN; Mertens B; van Vugt JP; Bachoud-Lévi AC; van Ommen GJ; Roos RA
J Neuropsychiatry Clin Neurosci; 2007; 19(3):310-7. PubMed ID: 17827417
[TBL] [Abstract][Full Text] [Related]
60. Unified Huntington's disease rating scale: a follow up.
Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
